Up and Coming
This feature highlights changes in clinical research organizations’ personnel.
AbGenomics Holding has named Judy Chou as the new president and chief executive officer. Chou was most recently senior vice president and global head of biotech at Bayer Pharmaceuticals as well as the site head of Berkeley, California, since 2017.
Alex Howarth has been appointed chief operating officer of Akcea Therapeutics. Howarth was previously president of Lycera.
Apexigen has named Jason Wright vice president of chemistry, manufacturing and controls and Thomas Jahn vice president of clinical development. Wright was most recently appointed vice president of manufacturing at Proclara Biosciences. Jahn previously served as the vice president for clinical development at RAPT Therapeutics.
Aptose Biosciences has named Rafael Bejar senior vice president and chief medical officer. Bejar was formerly associate professor of clinical medicine in the division of hematology and oncology at University of California San Diego Moores Cancer Center.
James Paskavitz has been named vice president of research and development at Aruna Bio. Paskavitz brings experience from his previous role as senior medical director at Sage Therapeutics.
José Iglesias has been named chief medical officer of Bioasis Technologies. Iglesias previously served as an oncology consultant in Toronto, Canada, and as the vice president and head of translational medicine at Boston Biomedical.
Philip Lambert has been appointed chief scientific officer at CENTOGENE. Lambert was previously senior vice president of discovery and labs as well as chief operating officer of two subsidiary companies of Life Biosciences, Selphagy Therapeutics and Spotlight Biosciences.
Shirley Zhao has been named the general manager for greater China and the head of commercial for CStone Pharmaceuticals. Before joining CStone pharmaceuticals, Zhao was the country general manager for Bristol Myers Squibb in China.
EpicentRx, has announced a new addition to its leadership team with the appointment of Franck Brinhaus as chief financial officer. Brinkhaus was previously the chief executive officer and founder of Biotech Alliances International in Silicon Valley, California.
Evecxia has appointed Jacob Jacobsen chief scientific officer. Jacobsen last served as a scientist in the Duke University lab of Marc Caron.
Patrick Flanigan III has been appointed chief financial officer and Martin Wilson has been appointed general counsel at Ichnos Sciences. Flanigan was most recently the senior vice president of investor relations and treasury for the Celgene Corporation. Wilson was general counsel of Teligent.
insitro has bolstered its leadership with the appointment of Serafim Batzoglou as chief data officer. Batzoglou previously served as a professor of computer science at Stanford University and vice president of applied and computational biology at Illumina.
Innovative Cellular Therapeutics
Innovative Cellular Therapeutics has expanded its senior management team with the appointment of Morten Marott as chief financial officer. Marott was most recently executive CFO at Veloxis Pharmaceuticals.
Ronald Martell has been named president and chief executive officer at Nuvelution Pharma. Martell was previously the founder and executive chairman of Indapta Immuno Therapeutics and chief executive officer at Achieve Life Sciences.
Anne Esposito has been appointed senior vice president of federal advocacy at the Pharmaceutical Research and Manufacturers of America. Esposito previously served as vice president of global government affairs for Indivior as well as advised members of Congress on health policy.
David Mims has been named interim chief executive officer at Progenics Pharmaceuticals. Mims previously served as president for U.S. specialty pharmaceuticals for Aptalis Pharma.
Rodney Young has been appointed chief financial officer at RAPT Therapeutics. Young previously served as the CFO of Cellerant Therapeutics.
Relay Therapeutics has appointed Ben Wolf chief medical officer, Mrunal “Monica” Phadnis vice president of clinical operations and Iain Martin vice president of drug metabolism and pharmacokinetics. Wolf was most recently CMO at KSQ Therapeutics. Phadnis was previously the executive director of clinical development in oncology and hematology at Syneos Health. Martin served as the executive director within the department of pharmacokinetics, pharmacodynamics and drug metabolism at Merck.